SCHEMBL3774633

SCHEMBL3774633

CC(C)(C)OC(=O)N1CCN(c2nc(-c3ccccc3Cl)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
LMNA P02545 5/20 0.52
TSHR P16473 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48
PBRM1 Q86U86 1/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MAPK1 P28482 4/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
SPR P35270 1/20 0.47
HTT P42858 1/20 0.47
FAAH O00519 2/20 0.47
USP30 Q70CQ3 1/20 0.46
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774289 0.92 MAPT (0.50) MAPTLMNATSHRNPSR1CNR1
SCHEMBL3761584 0.88 AR (0.58) MAPTLMNATSHRNPSR1CNR1
SCHEMBL3776873 0.87 SMN1; SMN2 (0.58) MAPTLMNATSHRNPSR1SMARCA2
SCHEMBL12781801 0.86 REV1 (0.52) MAPTLMNATSHRNPSR1SMARCA2
SCHEMBL18702282 0.86 RAB9A (0.55) MAPTLMNATSHRNPSR1CNR1
SCHEMBL3765754 0.84 RAB9A (0.66) MAPTLMNATSHRNPSR1NPC1
SCHEMBL18711651 0.84 RAB9A (0.53) MAPTLMNATSHRNPSR1CNR2
SCHEMBL3775088 0.83 MAPT (0.50) MAPTLMNATSHRNPSR1SMARCA2
SCHEMBL3767853 0.83 RAB9A (0.56) MAPTLMNATSHRNPC1RAB9A
SCHEMBL29157428 0.83 MAPT (0.74) MAPTLMNATSHRNPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
CN-101103007-A Amide compound TAKEDA PHARMACEUTICAL (JP) 2008-01-09 CN disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 MAPT 3805/4885LMNA 3346/4885TSHR 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.